Evidence map›Paper›PMID 38484189›Full record

ArticleBlood advances2024

A temporal developmental map separates human NK cells from noncytotoxic ILCs through clonal and single-cell analysis.

Dang Nghiem Vo, Ouyang Yuan, Minoru Kanaya, Gladys Telliam-Dushime, Hongzhe Li, Olga Kotova, Emel Caglar, Kristian Honnens de Lichtenberg, Shamim Herbert Rahman, Shamit Soneji and 4 more

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Resident CD49aScience advances · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Frontiers in immunology · 2025
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 3 countries.

Dang Nghiem VoLund Stem Cell Center, Lund University, Lund, Sweden.ORCID 0000-0003-1661-2020
Ouyang YuanLund Stem Cell Center, Lund University, Lund, Sweden.
Minoru KanayaDepartment of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID 0000-0002-0035-8657
Gladys Telliam-DushimeLund Stem Cell Center, Lund University, Lund, Sweden.
Hongzhe LiLund Stem Cell Center, Lund University, Lund, Sweden.
Olga KotovaLund Stem Cell Center, Lund University, Lund, Sweden.ORCID 0009-0007-6127-3925
Emel CaglarDivision of Molecular Hematology, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Kristian Honnens de LichtenbergCell Therapy Research, Novo Nordisk A/S, Måløv, Copenhagen, Denmark.ORCID 0000-0002-3905-9574
Shamim Herbert RahmanCell Therapy Research, Novo Nordisk A/S, Måløv, Copenhagen, Denmark.
Shamit SonejiLund Stem Cell Center, Lund University, Lund, Sweden.
Stefan SchedingLund Stem Cell Center, Lund University, Lund, Sweden.
David BryderLund Stem Cell Center, Lund University, Lund, Sweden.ORCID 0000-0002-8761-4237
Karl-Johan MalmbergDepartment of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID 0000-0002-8718-9373
Ewa SitnickaLund Stem Cell Center, Lund University, Lund, Sweden.ORCID 0000-0001-5332-7048
Lund University · SENovo Nordisk (Denmark) · DKOslo University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractNatural killer (NK) cells represent the cytotoxic member within the innate lymphoid cell (ILC) family that are important against viral infections and cancer. Although the NK cell emergence from hematopoietic stem and progenitor cells through multiple intermediate stages and the underlying regulatory gene network has been extensively studied in mice, this process is not well characterized in humans. Here, using a temporal in vitro model to reconstruct the developmental trajectory of NK lineage, we identified an ILC-restricted oligopotent stage 3a CD34-CD117+CD161+CD45RA+CD56- progenitor population, that exclusively gave rise to CD56-expressing ILCs in vitro. We also further investigated a previously nonappreciated heterogeneity within the CD56+CD94-NKp44+ subset, phenotypically equivalent to stage 3b population containing both group-1 ILC and RORγt+ ILC3 cells, that could be further separated based on their differential expression of DNAM-1 and CD161 receptors. We confirmed that DNAM-1hi S3b and CD161hiCD117hi ILC3 populations distinctively differed in their expression of effector molecules, cytokine secretion, and cytotoxic activity. Furthermore, analysis of lineage output using DNA-barcode tracing across these stages supported a close developmental relationship between S3b-NK and S4-NK (CD56+CD94+) cells, whereas distant to the ILC3 subset. Cross-referencing gene signatures of culture-derived NK cells and other noncytotoxic ILCs with publicly available data sets validated that these in vitro stages highly resemble transcriptional profiles of respective in vivo ILC counterparts. Finally, by integrating RNA velocity and gene network analysis through single-cell regulatory network inference and clustering we unravel a network of coordinated and highly dynamic regulons driving the cytotoxic NK cell program, as a guide map for future studies on NK cell regulation.

Indexed as

Killer Cells, NaturalSingle-Cell AnalysisCell DifferentiationCell LineageHumansImmunity, Innate

Identifiers

PMID38484189
PMCPMC11176970
OpenAlexW4392795376

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.